Metrics as of 10/13/2026, 06:57 PM (Berlin time), refresh in progress.
Novavax Stock
Novavax, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John Charles Jacobs
- Employees
- 749
- Market cap
- $2.1 B
- IPO
- 05/12/1995
Novavax, Inc. is a biotechnology company in the healthcare sector, headquartered in Gaithersburg, US. The firm is dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The diverse pipeline of the company includes…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Novavax stock: price history
1D
+0.6%
1W
+15.0%
1M
+34.5%
6M
+48.4%
YTD
+92.0%
1Y
+45.1%
2Y
+2.2%
5Y
-92.0%
10Y
-58.7%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~63% stronger price swings than usual
Novavax stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
2 more assignments (Enabler/Second row) Pro-only.
Novavax is a biotechnology company specializing in the research, development, and commercialization of vaccines against serious infectious diseases. Key products in its portfolio include vaccine candidates for COVID-19 (NVX-CoV2373), influenza (NanoFlu), and respiratory syncytial virus (RSV). The company generates revenue primarily through direct marketing of its products and supply contracts. Under a cooperation agreement with Takeda Pharmaceutical Company Limited, Novavax collaborates on the development, manufacturing, and distribution of its COVID-19 vaccine candidate.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Novavax
Analyst assessment of Novavax
PRICE TARGET LOW
US$11.00
CONSENSUS
US$18.00
MEDIAN
US$18.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
17
BUY
3
HOLD
3
SELL
0
STRONG SELL
23
TOTAL · Buy
As of: 11/06/2026
Novavax stock metrics
P/E
-8.43
P/B
-11.05
EV/EBITDA
-10.75
RETURN ON EQUITY
28.0%
NET MARGIN
-94.2%
DEBT/EQUITY
-1.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.0%
FLOAT SHARES
141,467,758
AVG. DAILY VOLUME (30D)
7,252,331
Insider transactions (SEC)
Alton Gregg H
MOTT DAVID M
MCGLYNN MARGARET G
DOUGLAS RICHARD
King Rachel K.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.6%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Novavax stock
What does Novavax do?
Novavax, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John Charles Jacobs, the company employs around 749 people.
The IPO was on 05/12/1995; the stock trades on NASDAQ under the ticker NVAX.
What do analysts say about Novavax stock?
23 analysts rate the stock, the consensus is Buy (as of 11/06/2026).
The average price target is US$18.00, ranging from US$11.00 to US$25.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Novavax report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 63% stronger than usual.
Does Novavax pay a dividend?
No, Novavax currently does not pay a dividend.
Which stocks are comparable to Novavax?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Novavax stock analyzed?
Clicking "Analyze stock" lets five strategies assess Novavax against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.